Major study evaluates effectiveness of cancer diagnosis pathway for patients with non-specific symptoms

The study, published today in the Lancet Primary Care, tracked over 4,800 patients referred to the SCAN Pathway between 2017 and 2023.

SCAN was originally developed in Oxfordshire in partnership with NHS England, Cancer Research UK and Macmillan Cancer Support; it aimed to accelerate and streamline cancer diagnosis for patients with symptoms that fall outside standard urgent referral guidelines. Since 2020, it has been adopted as standard care across the region and is part of the NHS's wider rollout of Rapid Diagnostic Centres nationwide.

Early diagnosis of cancers could save thousands of lives each year and significantly reduce treatment costs for the NHS, as late-stage cancer care is considerably more expensive.

Key findings:

• Over the six years tracked, 8.8% of patients were diagnosed with cancer, most commonly lung, pancreatic, breast, non-Hodgkin lymphoma, and colorectal.
• An additional 10.9% received serious non-cancer diagnoses.
• 19.3% had clinically significant incidental findings, underscoring the complexity and resource demands of these pathways.
• Certain combinations of symptoms and test abnormalities significantly increased the likelihood of a cancer diagnosis. For example, abnormal CA125 levels (a protein found in the blood which can be used as a biomarker for detecting some cancers) had a 29.7% positive predictive value for cancer.

Dr. Claire Friedemann Smith, joint first author and researcher at the Nuffield Department of Primary Care Health Sciences, University of Oxford, said: "Our findings support the value of non-specific symptom pathways like SCAN in identifying hard-to-diagnose cancers, but they also highlight the considerable number of incidental findings that can place additional pressure on healthcare systems. This study gives vital insights for clinicians, commissioners, and policymakers aiming to improve early diagnosis without overwhelming services."

The study’s extended time frame also allowed researchers to assess how patient characteristics, outcomes, and pathway performance evolved from its initial pilot phase to full integration into routine NHS care.

This evidence reinforces the importance of appropriately resourcing NSS pathways, especially as similar diagnostic models are adopted across the UK and internationally. The study also calls for further research into the cost-effectiveness of these pathways, particularly in light of the substantial number of non-cancer findings and lack of stage shift in cancers diagnosed.

Dr. Brian D Nicholson, joint first author and researcher at the Nuffield Department of Primary Care Health Sciences, University of Oxford, added: “We are pleased to present the findings from SCAN’s first six years. There is a careful balance to strike when intensively investigating non-specific symptoms between the identification of disease caused by the symptom that requires immediate treatment and incidental findings of unknown significance. Using our research database we will now work to identify the additional serious diseases detected during the follow-up of incidental findings to help optimise non-specific symptom pathways in the NHS.”

Find out more about accessing clinical data or samples from the SCAN Pathway on the Oxford Cancer website. Whether you're developing biomarkers, validating AI models, or exploring symptom pathways, SCAN offers a rich, well-curated resource to accelerate your work.

Notes to Editors

For interviews with Dr. Claire Friedemann Smith, please contact Christopher McIntyre at the University of Oxford’s Press Office: news.office@admin.ox.ac.uk

About the University of Oxford

Oxford University has been placed number 1 in the Times Higher Education World University Rankings for the ninth year running, and ​number 3 in the QS World Rankings 2024. At the heart of this success are the twin-pillars of our ground-breaking research and innovation and our distinctive educational offer.

Oxford is world-famous for research and teaching excellence and home to some of the most talented people from across the globe. Our work helps the lives of millions, solving real-world problems through a huge network of partnerships and collaborations. The breadth and interdisciplinary nature of our research alongside our personalised approach to teaching sparks imaginative and inventive insights and solutions.

Through its research commercialisation arm, Oxford University Innovation, Oxford is the highest university patent filer in the UK and is ranked first in the UK for university spinouts, having created more than 300 new companies since 1988. Over a third of these companies have been created in the past five years. The university is a catalyst for prosperity in Oxfordshire and the United Kingdom, contributing around £16.9 billion to the UK economy in 2021/22, and supports more than 90,400 full time jobs.